stockrowPulse Biosciences, Inc
PLSE Healthcare Medical Instruments & Supplies
Pulse Biosciences, Inc’s revenue for fiscal 2025 (year ended December 2025) was $350,000.00, down 50.0% from fiscal 2022.
- Revenue
- +359.3%
- EPS
- −10.3%
- Free cash flow
- −1,180.5%
Quarter to September 2026, against a year earlier
Follow PLSE
Alert me
Pulse Biosciences, Inc (PLSE) Return on invested capital
Pulse Biosciences, Inc's return on invested capital over the twelve months to 30 September 2026 was −37.0%, down 37.0 percentage points from fiscal 2025 (0.00%). Over the past ten years it has ranged from −1,434.2% (fiscal 2022) to 0.00% (fiscal 2025) — the current reading is the highest in ten years. That is below the Medical Instruments & Supplies industry median of 0.13% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 0.00% | 0.00 |
| FY2024 | 0.00% | 0.00 |
| FY2023 | 0.00% | 1,434.21 |
| FY2022 | −1,434.2% | (1,219.30) |
| FY2021 | −214.9% | 11.79 |
| FY2020 | −226.7% | 21.86 |
| FY2019 | −248.6% | 102.90 |
| FY2018 | −351.5% | (147.91) |
| FY2017 | −203.6% | (136.26) |
| FY2016 | −67.3% | (39.53) |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| NVST Envista Holdings Corporation compare | 13.6% |
| MMSI Merit Medical Systems, Inc. compare | 6.87% |
| STVN Stevanato Group S.p.A. compare | 6.71% |
| ATRC AtriCure, Inc. compare | 2.61% |
| ICUI ICU Medical, Inc. compare | 2.27% |
| WRBY Warby Parker Inc. compare | 0.83% |
| TFX Teleflex Incorporated compare | 0.51% |
| MMED MiniMed Group, Inc. compare | −1.61% |
| PLSE Pulse Biosciences, Inc | −37.0% |
| Medical Instruments & Supplies industry median | 0.13% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on PLSE
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Altman Z-score
- The full statement